Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Frank Morich is Director at Perspective Therapeutics. OQRO lists 2 transactions filed with the SEC under this name, the latest on Nov 17, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
2 purchases disclosed. $1,000 placed after each of the 1 purchases disclosed since 2025-11-18 would be worth $1K today ($1K put in); the same in the S&P 500 (SPY): $1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.0 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Perspective TherapeuticsCATX
2 disclosures · Nov 2026 · 2 bought
Nov 16, 2026Bought~$14Kdisclosed Nov 17
DetailsOfficial recordNov 12, 2026Bought~$15Kdisclosed Nov 16
DetailsOfficial recordFrank Morich bought shares on the open market in 2022 and 2026 across 2 companies.
Frank Morich reported 3 open-market purchases and 0 sales since 2022; purchases in 2 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $29K2×2 trades | — |
| 2022 | $105K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Frank Morich reported holding 30,000 shares of Perspective Therapeutics (CATX), worth about $26K at the last close of $1 (Nov 17, 2026). In the last 12 months, Frank Morich bought $29K in 2 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Perspective Therapeutics CATX | 30,000 | 30K direct | $1 | $26K | Nov 16, 2026 |
Is this Frank Morich’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Nov 16, 2026, Frank Morich reported holding 30,000 shares of Perspective Therapeutics (CATX). At the last close of $1 on Nov 17, 2026, that is about $26K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Frank Morich reported 2 open-market purchases worth $29K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Frank Morich bought shares on the open market in 2022 and 2026 across 2 companies.
In SEC filings since 2022: the latest open-market purchase is from 2026; no open-market sale is on record.
2 companies: Perspective Therapeutics (CATX, 2026), Cue Biopharma (CUE, 2022).
Frank Morich reported 2 open-market purchases and 0 sales here, 2026.
Frank Morich reported 1 open-market purchase and 0 sales here, 2022.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.